Related Experiment Videos

Oncology clinical trials

P Mellody1, A Dehgan

  • 1Quality Operating Solutions, Los Angeles, Calif., USA.

The Case Manager
|November 4, 2000
PubMed

Insights

The "war on cancer" has led to a decline in cancer rates since the 1930s. Continued biomedical advances promise further reductions in cancer incidence and mortality.

Area of Science:

  • Oncology
  • Public Health
  • Biomedical Science

Background:

  • The National Cancer Program, initiated in 1971, has seen sustained investment.
  • Cancer incidence and mortality have been tracked by major health organizations.
  • Significant progress has been made in understanding and combating cancer.

Purpose of the Study:

  • To review the impact of the National Cancer Program on cancer statistics.
  • To highlight recent trends in cancer incidence and mortality.
  • To project future impacts of scientific and technological advancements on cancer outcomes.

Main Methods:

  • Analysis of cancer statistics from the National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), and American Cancer Society (ACS).
  • Review of historical funding and investment in cancer research.
  • Assessment of emerging biomedical and technological developments relevant to cancer treatment and prevention.

Main Results:

  • Cancer statistics show the first significant decline since the 1930s.
  • Over 1.2 million Americans are diagnosed with cancer annually.
  • Sustained investment in the National Cancer Program demonstrates a positive return.

Conclusions:

  • The "war on cancer" has yielded measurable success in reducing cancer rates.
  • Ongoing scientific and technological advancements are expected to further decrease cancer incidence and mortality.
  • Continued research and investment are crucial for future progress in oncology.

Related Concept Videos